156 related articles for article (PubMed ID: 32306475)
21. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.
van der Veer A; Waanders E; Pieters R; Willemse ME; Van Reijmersdal SV; Russell LJ; Harrison CJ; Evans WE; van der Velden VH; Hoogerbrugge PM; Van Leeuwen F; Escherich G; Horstmann MA; Mohammadi Khankahdani L; Rizopoulos D; De Groot-Kruseman HA; Sonneveld E; Kuiper RP; Den Boer ML
Blood; 2013 Oct; 122(15):2622-9. PubMed ID: 23974192
[TBL] [Abstract][Full Text] [Related]
22. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.
Martinelli G; Iacobucci I; Storlazzi CT; Vignetti M; Paoloni F; Cilloni D; Soverini S; Vitale A; Chiaretti S; Cimino G; Papayannidis C; Paolini S; Elia L; Fazi P; Meloni G; Amadori S; Saglio G; Pane F; Baccarani M; Foà R
J Clin Oncol; 2009 Nov; 27(31):5202-7. PubMed ID: 19770381
[TBL] [Abstract][Full Text] [Related]
23. Poor responses to tyrosine kinase inhibitors in a child with precursor B-cell acute lymphoblastic leukemia with SNX2-ABL1 chimeric transcript.
Masuzawa A; Kiyotani C; Osumi T; Shioda Y; Iijima K; Tomita O; Nakabayashi K; Oboki K; Yasuda K; Sakamoto H; Ichikawa H; Hata K; Yoshida T; Matsumoto K; Kiyokawa N; Mori T
Eur J Haematol; 2014 Mar; 92(3):263-7. PubMed ID: 24215620
[TBL] [Abstract][Full Text] [Related]
24. Detection of a cryptic
Peterson JF; Pitel BA; Smoley SA; Smadbeck JB; Johnson SH; Vasmatzis G; Koon SJ; Webley MR; McGrath M; Bayerl MG; Baughn LB; Rowsey RA; Ketterling RP; Greipp PT; Hoppman NL
Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30936193
[TBL] [Abstract][Full Text] [Related]
25. Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review.
Tan KW; Zhu YY; Qiu QC; Wang M; Shen HJ; Huang SM; Cao HY; Wan CL; Li YY; Dai HP; Xue SL
Ann Hematol; 2023 Sep; 102(9):2397-2402. PubMed ID: 37103615
[TBL] [Abstract][Full Text] [Related]
26. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.
Mullighan CG; Miller CB; Radtke I; Phillips LA; Dalton J; Ma J; White D; Hughes TP; Le Beau MM; Pui CH; Relling MV; Shurtleff SA; Downing JR
Nature; 2008 May; 453(7191):110-4. PubMed ID: 18408710
[TBL] [Abstract][Full Text] [Related]
27. Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia.
Cazzaniga G; van Delft FW; Lo Nigro L; Ford AM; Score J; Iacobucci I; Mirabile E; Taj M; Colman SM; Biondi A; Greaves M
Blood; 2011 Nov; 118(20):5559-64. PubMed ID: 21960589
[TBL] [Abstract][Full Text] [Related]
28. High frequency of BTG1 deletions in patients with BCR-ABL1-positive acute leukemia.
Xie J; Wang Q; Wang Q; Yao H; Wen L; Ma L; Wu D; Chen S
Cancer Genet; 2014 May; 207(5):226-30. PubMed ID: 24998463
[TBL] [Abstract][Full Text] [Related]
29. Dasatinib and allogeneic stem cell transplantation enable sustained response in an elderly patient with
Frech M; Jehn LB; Stabla K; Mielke S; Steffen B; Einsele H; Metzelder SK; Neubauer A
Haematologica; 2017 Apr; 102(4):e160-e162. PubMed ID: 28057740
[No Abstract] [Full Text] [Related]
30. Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion.
Moorman AV; Schwab C; Winterman E; Hancock J; Castleton A; Cummins M; Gibson B; Goulden N; Kearns P; James B; Kirkwood AA; Lancaster D; Madi M; McMillan A; Motwani J; Norton A; O'Marcaigh A; Patrick K; Bhatnagar N; Qureshi A; Richardson D; Stokley S; Taylor G; van Delft FW; Moppett J; Harrison CJ; Samarasinghe S; Vora A
Br J Haematol; 2020 Dec; 191(5):844-851. PubMed ID: 32926422
[TBL] [Abstract][Full Text] [Related]
31. Characterization of leukemias with ETV6-ABL1 fusion.
Zaliova M; Moorman AV; Cazzaniga G; Stanulla M; Harvey RC; Roberts KG; Heatley SL; Loh ML; Konopleva M; Chen IM; Zimmermannova O; Schwab C; Smith O; Mozziconacci MJ; Chabannon C; Kim M; Frederik Falkenburg JH; Norton A; Marshall K; Haas OA; Starkova J; Stuchly J; Hunger SP; White D; Mullighan CG; Willman CL; Stary J; Trka J; Zuna J
Haematologica; 2016 Sep; 101(9):1082-93. PubMed ID: 27229714
[TBL] [Abstract][Full Text] [Related]
32. Two novel fusion genes, AIF1L-ETV6 and ABL1-AIF1L, result together with ETV6-ABL1 from a single chromosomal rearrangement in acute lymphoblastic leukemia with prenatal origin.
Lukes J; Potuckova E; Sramkova L; Stary J; Starkova J; Trka J; Votava F; Zuna J; Zaliova M
Genes Chromosomes Cancer; 2018 Sep; 57(9):471-477. PubMed ID: 29726059
[TBL] [Abstract][Full Text] [Related]
33. Monitoring of childhood ALL using
Hovorkova L; Zaliova M; Venn NC; Bleckmann K; Trkova M; Potuckova E; Vaskova M; Linhartova J; Machova Polakova K; Fronkova E; Muskovic W; Giles JE; Shaw PJ; Cario G; Sutton R; Stary J; Trka J; Zuna J
Blood; 2017 May; 129(20):2771-2781. PubMed ID: 28331056
[TBL] [Abstract][Full Text] [Related]
34. Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates.
Boer JM; Koenders JE; van der Holt B; Exalto C; Sanders MA; Cornelissen JJ; Valk PJ; den Boer ML; Rijneveld AW
Haematologica; 2015 Jul; 100(7):e261-4. PubMed ID: 25769542
[No Abstract] [Full Text] [Related]
35. RCSD1-ABL1-positive B lymphoblastic leukemia is sensitive to dexamethasone and tyrosine kinase inhibitors and rapidly evolves clonally by chromosomal translocations.
Inokuchi K; Wakita S; Hirakawa T; Tamai H; Yokose N; Yamaguchi H; Dan K
Int J Hematol; 2011 Sep; 94(3):255-260. PubMed ID: 21863287
[TBL] [Abstract][Full Text] [Related]
36. Acute leukemias with ETV6/ABL1 (TEL/ABL) fusion: poor prognosis and prenatal origin.
Zuna J; Zaliova M; Muzikova K; Meyer C; Lizcova L; Zemanova Z; Brezinova J; Votava F; Marschalek R; Stary J; Trka J
Genes Chromosomes Cancer; 2010 Oct; 49(10):873-84. PubMed ID: 20589932
[TBL] [Abstract][Full Text] [Related]
37. High incidence of RAS pathway mutations among sentinel genetic lesions of Korean pediatric BCR-ABL1-like acute lymphoblastic leukemia.
Lee JW; Kim Y; Cho B; Kim S; Jang PS; Lee J; Cho H; Lee GD; Chung NG; Kim M
Cancer Med; 2020 Jul; 9(13):4632-4639. PubMed ID: 32378810
[TBL] [Abstract][Full Text] [Related]
38. NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors.
Duployez N; Grzych G; Ducourneau B; Alarcon Fuentes M; Grardel N; Boyer T; Abou Chahla W; Bruno B; Nelken B; Clappier E; Preudhomme C
Haematologica; 2016 Apr; 101(4):e133-4. PubMed ID: 26681761
[No Abstract] [Full Text] [Related]
39. Recurrent Fusion of the GRB2 Associated Binding Protein 1 (
Panagopoulos I; Gorunova L; Andersen K; Tafjord S; Lund-Iversen M; Lobmaier I; Micci F; Heim S
Cancer Genomics Proteomics; 2020; 17(5):499-508. PubMed ID: 32859628
[TBL] [Abstract][Full Text] [Related]
40. Beyond Philadelphia: 'Ph-like' B cell precursor acute lymphoblastic leukemias - diagnostic challenges and therapeutic promises.
Izraeli S
Curr Opin Hematol; 2014 Jul; 21(4):289-96. PubMed ID: 24848770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
